WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) has issued General Correspondence Letters to two third-party testing companies in China after uncovering falsified or otherwise invalid ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback